



A.O. S. Croce e Carle di Cuneo

Titolo:	A PHASE 2 AND PHASE 3 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPIMAB COMPARED WITH ANTI-PD1 ALONE IN PATIENTS WITH RESECTABLE STAGE III AND IV MELANOMA
Patologia:	Melanoma
Tipo di Studio:	Interventistico farmacologico
Fase:	2 and 3
Principali criteri di inclusione:	All patients must be either stage III (IIIB, IIIC, IIID) or stage IV (M1a, M1b, M1c) per AJCC 8th edition (Amin 2017) and have histologically confirmed cutaneous melanoma that is deemed completely surgically resectable. Patients with stage III melanoma must have clinically detectable disease that is confirmed as malignant on the pathology report. The pathology report must be reviewed, signed and dated by the investigator; this process will be confirmed during the IVRS process.
Principali criteri di esclusione:	Ongoing or recent (within 2 years) evidence of an autoimmune disease that required systemic treatment with immunosuppressive agents. The following are nonexclusionary: vitiligo, childhood asthma that has resolved, residual hypothyroidism that requires only hormone replacement, psoriasis not requiring systemic treatment. Patients must not have received any prior systemic anti-cancer therapy for melanoma. Prior radiotherapy for melanoma is allowed if not given to a target lesion or, if given to a target lesion, there is pathological evidence of disease progression in the same lesion.
Sede e contatti	AO S. Croce e Carle ctc@ospedale.cuneo.it 0171641539